Fig. 6: Assessing monitoring and surveillance of IDH1.R132H mutant gliomas during the course of clinical therapy.
From: Clinical utility of a blood based assay for the detection of IDH1.R132H-mutant gliomas
a–c Testing of the optimized ddPCR assay in plasma samples (2 ml) collected longitudinally in a cohort of n = 8 (labeled, P1-P8) patients. Individual graphs summarizing the EV RNA IDH1.R132H, MAF % (y-axis, mean of 8 replicates) at each clinical time-point (x-axis, time elapsed from baseline detection) with the affiliated radiological findings and clinical outcomes. Study population divided into three groups based on clinical outcomes: (a) disease progression, (b) treatment response, and (c) stable disease. d Line plot (third panel, bottom-right) demonstrating the overall trend in measured EV RNA IDH1.R132H MAF % (normalized, described in methods) levels at selected clinical timepoints of treatment: pre-, early- and post- therapy. GTR: Gross total resection, STR: Sub-total resection, Proton RT: Proton therapy, TMZ: Temozolamide, RT: Radiation therapy, PCV: Procarbazine, Lomustine, and Vincristine. Source Data are provided as a Source Data file. Figure 6/A-C Created with BioRender.com released under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International license (https://creativecommons.org/licenses/by-nc-nd/4.0/deed.en).
